

– Press Release –

LFB BIOMANUFACTURING SITE IN ALÈS WILL DOUBLE ITS BIOMEDICINAL PRODUCTION CAPACITY

Alès (Gard), 14 June 2024 – Today, under the sponsorship of Catherine Vautrin, French Minister of Labour, Health and of Solidarity and Lise Alter, Managing Director of the French Health Innovation Agency, LFB BIOMANUFACTURING laid the groundwork for a new capacity expansion of its industrial site in Alès. This project of LFB BIOMANUFACTURING, a subsidiary of LFB specialising in the production of therapeutic proteins, including monoclonal antibodies, by cell culture, is co-financed by the French government via the “France 2030” plan and will ultimately allow the site to double its production capacity as well as create around fifty jobs. This expansion comes in a context marked by the growing demand for biomedicinal products, both in France and worldwide.

A strategic project co-financed by the “France 2030” plan

Launched for the benefit of patients and to further national and European health sovereignty, for a total cost of more than 20 million euros, this project is fully in line with the objectives of “France 2030” and the Biotherapies / Bioproduction acceleration strategy of France’s Health Innovation 2030 plan. And it was on these premises that the planned expansion obtained financial support from the French government of up to 6.7 million euros.

The expansion of the site, with the creation of around fifty jobs by 2026, is even more crucial at a time when the health industry sector is undergoing a real revolution: the arrival of medicinal products whose active substances are produced from live organisms. Today, 59% of medicinal products in development worldwide are biotherapies¹.

This investment will allow the Alès site to provide its customers with doubled production capacities of 2x 2,000 litres. This expansion will also include development and analytical service laboratories and raw material warehouse.

As an FDA² approved CDMO³, the Alès site shares its know-how and equipment with customers, including support for the development of cell lines and processes on an industrial scale, the manufacture of clinical and commercial batches as well as the associated analytical testing.

Because CDMO capacity in France is currently insufficient, national players are too often forced to produce in other countries. This expansion of LFB BIOMANUFACTURING’s site in Alès is therefore strategic: it will help meet the growing needs of French biotech companies looking to produce therapeutic proteins in France.

1

<https://www.info.gouv.fr/upload/media/content/0001/08/8d48956285047d0a1b5305733c17f6bab0501578.pdf>

² Food and Drug Administration

³ Contract Development and Manufacturing Organization

In the words of Catherine Vautrin, French Minister of Labour, Health and Solidarity: *“LFB’s investment in its Alès industrial site marks an important step towards strengthening France’s health and industrial sovereignty. It will also lead to the creation of fifty jobs in the region and constitutes a concrete response to the growing bioproduction needs of French biotech companies. I congratulate them for their commitment and reiterate the full support of the French government as a full partner thanks to the financial support provided as part of the “France 2030” program.”*

For Lise Alter, Managing Director of the French Health Innovation Agency: *“One of the objectives of “France 2030” is to support projects that will allow France to produce the treatments of tomorrow, and the expansion of LFB’s Alès site is an important contribution in that direction. Biomedicinal products and in particular the family of therapeutic proteins represent hope for many patients. Being able to produce the treatments they need, on our territory, is essential. This project will also help promote French bioproduction excellence within Europe and around the world.”*

For Jacques Brom, CEO of LFB: *“The expansion of our Alès site with the sponsorship of Ms Catherine Vautrin, French Minister of Labour, Health and Solidarity, is a significant step towards strengthening the French bioproduction sector. At a time when patient needs for biomedicinal products continue to increase, this investment will allow us to double our bioproduction capacities in Alès, while also contributing to local employment and offering the excellence of our industrial know-how.”*

About LFB

LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases. Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care. LFB’s current market portfolio includes 15 biomedicinal products sold in about 30 countries.

For more information on LFB, go to www.groupe-lfb.com.

About LFB BIOMANUFACTURING

LFB BIOMANUFACTURING, one of the key entities in the LFB group’s bioproduction activities, operates the Alès (Gard department) industrial site specialising in the manufacture of recombinant medicinal products by cell culture, and of recombinant proteins and monoclonal antibodies in particular.

LFB BIOMANUFACTURING acts as a CDMO to offer its customers bioproduction services ranging from the development of cell lines to the manufacture of recombinant medicinal products compliant with GMP standards. On its FDA-approved industrial site in Alès, LFB BIOMANUFACTURING also manufactures a recombinant coagulation factor for the LFB group, as well as clinical and commercial batches on behalf of third parties.

For more information on LFB BIOMANUFACTURING, go to <https://www.lfbbiomanufacturing.com/fr/>

LFB contact person:

Didier Véron – Executive Vice President, Corporate Affairs

Phone: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54 - Email: verondidier@lfb.fr

About France 2030

The France 2030 investment plan:

- Aims to meet two important objectives: to sustainably transform key sectors of our economy (health, energy, automotive, aeronautics and even space) through technological innovation, and to position France not just as a player, but as a leader in the world of tomorrow. France 2030 supports the entire life cycle of innovation, starting from fundamental research and the emergence of an idea, through to industrialization of the process and the production of a new product or service.
- France 2030 is unprecedented in its scale: €54 billion is being invested so that our businesses, our schools, our universities and our research organizations fully succeed with their transitions in these strategic sectors. The challenge is to enable them to respond in a competitive way to the world's future ecological and attractiveness challenges, and to showcase the future champions of our sectors of excellence. France 2030 is defined by two overarching objectives, which will see 50% of expenses given over to the decarbonization of the economy, and 50% to emerging key players, those at the forefront of innovation, without neglecting the environment (in the sense of the "Do No Significant Harm" principle).
- France 2030 is being implemented collectively: designed and deployed in consultation with economic, academic, local and European key players to establish strategic guidelines and decisive action. Project holders are invited to submit their entries via the current application process, which is a demanding and selective one, to benefit from state support.
- France 2030 is being led by the French General Secretariat for Investment, in charge of France 2030, on behalf of the Prime Minister, and in partnership with the relevant government ministries. France 2030 is being implemented by the French National Research Agency (ANR), the French Agency for Ecological Transition (ADEME), Bpifrance and the Caisse des Dépôts et consignation (CDC).

For more information, go to: <https://www.gouvernement.fr/france-2030> | @SGPI_avenir